

Manitoba Biosimilars Initiative

Completed Biosimilar Transition Periods

Drug Name	Reference Biologic (Switch from)	Biosimilar (Switch to)	Health Conditions*	Transition Period End Date
Adalimumab	Humira	Abrilada Amgevita Hadlima Hulio Hyrimoz Idacio Simlandi Yuflyma	Ankylosing Spondylitis Crohn's Disease Hidradenitis Suppurativa Plaque Psoriasis Polyarticular Juvenile Idiopathic Arthritis Psoriatic Arthritis Rheumatoid Arthritis Ulcerative Colitis	January 31, 2025
Enoxaparin	Lovenox	Elonox Elonox HP Inclunox Inclunox HP Noromby Noromby HP Redesca Redesca HP	Prevention and treatment of venous thromboembolic events	January 31, 2025
Etanercept	Enbrel	Brenzys Erelzi Rymti	Ankylosing Spondylitis Plaque Psoriasis Polyarticular Juvenile Idiopathic Arthritis Psoriatic Arthritis Rheumatoid Arthritis	January 31, 2025

Drug Name	Reference Biologic (Switch from)	Biosimilar (Switch to)	Health Conditions*	Transition Period End Date
Filgrastim	Neupogen	Grastofil Nivestym Nypozi	Prevention and treatment of neutropenia	January 31, 2025
Glatiramer (a non-biologic complex drug)	Copaxone	Glatect	Multiple Sclerosis	January 31, 2025
Infliximab	Remicade	Avsola Inflectra Renflexis	Ankylosing Spondylitis Crohn's Disease Plaque Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Ulcerative Colitis	January 31, 2025
Insulin aspart	NovoRapid	Kirsty Trurapi	Diabetes	January 31, 2025
Insulin glargine	Lantus	Basaglar Semglee	Diabetes	January 31, 2025
Insulin lispro (100 units/mL)	Humalog	Admelog	Diabetes	January 31, 2025
Rituximab	Rituxan	Riximyo Ruxience Truxima	Granulomatosis with Polyangiitis Microscopic Polyangiitis Rheumatoid Arthritis	January 31, 2025

Please note:

- Coverage of Humalog 200 units/mL will continue to be available for patients who need a higher concentration formula, as there is no equivalent biosimilar version available at this time.
- Coverage of Lantus cartridges will continue to be available for pediatric patients who require a half-unit pen device to administer insulin glargine.

- Coverage of NovoRapid vials will continue to be available for patients who use vials for an insulin pump, while biosimilars undergo insulin pump certification, and until these biosimilar(s) in a vial format are available / listed on the Manitoba Drug Benefits Formulary.
- Admelog is compatible with various insulin pump models from Insulet (Omnipod), Medtronic, Tandem, and Ypsomed.
- Individuals with questions about insulin compatibility with specific insulin pump models are encouraged to contact the insulin pump manufacturer.